Fanconi anemia, dyskeratosis congenita, and WT syndrome

1987 ◽  
Vol 28 (S3) ◽  
pp. 263-278 ◽  
Author(s):  
Nasrollah T. Shahidi ◽  
John M. Opitz ◽  
Jay Bernstein
Hematology ◽  
2004 ◽  
Vol 2004 (1) ◽  
pp. 318-336 ◽  
Author(s):  
Grover C. Bagby ◽  
Jeffrey M. Lipton ◽  
Elaine M. Sloand ◽  
Charles A. Schiffer

Abstract New discoveries in cell biology, molecular biology and genetics have unveiled some of the pathophysiological mysteries of some of the bone marrow failure syndromes. Many of these discoveries have revealed why these syndromes show so much clinical overlap and some hold the potential for influencing the development of new therapies. In children and adults with pancytopenia and hypoplastic bone marrows proper differential diagnosis requires that some attention be directed toward defining molecular and cellular pathogenetic mechanisms because, once identified, some of these mechanisms will clearly suggest rational therapeutic approaches, treatment options that should be avoided, or both. In Section I, Drs. Jeffrey Lipton and Grover Bagby review the approach to diagnosis and management of patients with the inherited bone marrow failure syndromes, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, and the Shwachman-Diamond syndrome. Extraordinary progress has been made in identifying the genes bearing pathogenetically relevant mutations in these disorders, but slower progress has been made in defining the precise functions of the proteins these genes encode in normal cells, in part because it is increasingly obvious that the proteins are multifunctional. In practice, it is clear that in patients with dyskeratosis congenita and Fanconi anemia, the diagnosis must be considered not only in children but in adults as well. In Section II, Dr. Elaine Sloand outlines a very practical and evidence-based approach to diagnosis and management of acquired hypoplastic states emphasizing overlap between non-clonal and clonal hematopoiesis is such conditions. The pathogenesis of T lymphocyte–mediated marrow failure is presented as a clear-cut rationale for use of immunosuppressive therapy and stem cell transplantation. Practical management of patients with refractory disease with and without evidence of clonal evolution (either paroxysmal nocturnal hemoglobinuria [PNH] or myelodysplasia [MDS]) is presented. In Section III, the challenge of hypoplastic MDS is reviewed by Dr. Charles Schiffer. After reviewing the most up-to-date classification scheme, therapeutic options are reviewed, focusing largely on agents that have most recently shown some promising activity, including DNA demethylating agents, thalidomide and CC5013, arsenic trioxide, and immunosuppressive therapy. Here are also outlined the rationale and the indications for choosing allogeneic bone marrow transplantation, the only therapy with known curative potential.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 5563-5563
Author(s):  
Blanche P Alter ◽  
Neelam Giri ◽  
Sharon H Savage

5563 Background: Fanconi Anemia (FA) and dyskeratosis congenita (DC) are inherited bone marrow failure syndromes (IBMFS) with extraordinarily high risks of cancer, particularly head and neck squamous cell carcinoma (HNSCC). The standardized incidence ratios (SIR) for solid tumors are 40 in FA and 10 in DC, and for HNSCC 700 and 900 respectively. In the general population, cancers of the oropharynx may be associated with human papilloma virus (HPV) more than the oral cavity. The specific locations of HNSCC in FA and DC have not been reviewed, and thus the hypothetical role of HPV in these cancers is unknown. Methods: Literature cases were reviewed through PubMed searches using the terms “Fanconi anemia” and “dyskeratosis congenita”. All papers were reviewed, and details of the specific cancers recorded. FA literature included reports from 1927 through 2011, and DC literature from 1910 through 2011. Participants in the National Cancer Institute (NCI) IBMFS retrospective/prospective protocol (NCI 02-C-0052, opened in 2002) were also analyzed for cancer. The HPV vaccine was not available during most of the time frame of this study. Results: There were 411 cases of cancer among 2190 (19%) cases of FA described individually in the literature, and 21 cancer cases out of 116 (18%) FA patients in the NCI cohort. HNSCC were reported in 112 FA literature cases (5%), and 9 (8%) in the cohort. The oropharynx was the initial site for HNSCC in 31/112 literature cases (28%) and 3/9 NCI cases (33%). With regard to DC, 51/647 (8%) cases in the literature had cancer, as did 9 of 94 (10%) NCI participants. HNSCC were reported in 21/647 (3%) DC literature cases, and in 5/94 (5%) from the NCI cohort. Four of the 21 HNSCC (19%) in the literature were oropharyngeal, and 2/5 (40%) in the NCI cohort. The cumulative incidences of any HNSCC in the NCI FA and DC cohorts were 50% and 21% by 40 years of age (censored at death from other causes). Conclusions: Patients with FA and DC have extremely high risks of HNSCC at substantially younger ages than the general population. Approximately 30% of these cancers occur in the oropharynx. The HPV vaccine could be important in prevention of these cancers. Future studies of the HPV status of oral cavity and oropharynx HNSCC tumors from patients with FA and DC will be informative.


2003 ◽  
pp. 3-18
Author(s):  
Alex J. Tipping ◽  
Tom J. Vulliamy ◽  
Neil V. Morgan ◽  
Inderjeet Dokal

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1052-1052 ◽  
Author(s):  
Rodrigo T. Calado ◽  
Tullia Bruno ◽  
Keisha L. Wilkerson ◽  
Neal S. Young

Abstract Aplastic anemia is characterized by peripheral blood pancytopenia and a hypocellular bone marrow. In the majority of patients, bone marrow destruction is immune-mediated by a type-1 T cell response, dominated by oligoclonal expansion of CD8+ cells and targeting hematopoietic stem cells. Some patients with acquired aplastic anemia are heterozygous for mutations in genes encoding the major components of the telomerase complex, telomerase reverse transcriptase (encoded by TERT; Yamaguchi et al., N Engl J Med2005;352:1413) and the RNA component (encoded by TERC; Fogarty et al., Lancet2003;362:1628). These mutations lead to shortened telomeres of leukocytes, low telomerase activity and reduced hematopoietic function. Relatives carrying the same mutations also have short telomeres and reduced hematopoietic function, but they do not inevitably develop overt marrow failure. In contrast, dyskeratosis congenita, a constitutional type of marrow failure, is caused by mutations in TERC (autosomal dominant type) or in the DKC1 gene, which encodes an additional component of the telomerase complex, dyskerin. In addition to marrow failure, patients with dyskeratosis congenita also often have physical anomalies, such as leukoplakia, nail dystrophy, and hyperpigmentation as well as hepatic or pulmonary fibrosis. In dyskeratosis congenita, family members bearing the genetic mutation present variable degrees of physical abnormalities or organ damage. However, in patients with acquired aplastic anemia carrying telomerase mutations without physical anomalies, it is unclear whether these mutations are sufficient for the development of marrow failure. We hypothesized that telomerase complex mutations reduce the size of the hematopoietic stem cell compartment and affect its regenerative capacity, making carriers more vulnerable to environmental insults or autoimmune damage. We analyzed the distribution of the T-cell repertoire (T-cell receptor [TCR] Vβ subfamily) and expansion of particular Vβ subsets by flow cytometry in peripheral blood of six aplastic anemia patients carrying telomerase complex mutations (five with TERT mutations, one with a TERC mutation), two patients with Fanconi anemia, and 15 healthy subjects. The expression of 22 Vβ subfamilies were evaluated in CD8+CD28− cells, and expansion was defined when the percentage of a given Vβ subfamily was above two standard deviations based on the control group (Risitano et al. Lancet2004;364:355). We also evaluated interferon-γ levels in serum of nine telomerase mutant patients and 10 controls by ELISA. Expanded Vβ subsets were observed in all six aplastic patients carrying telomerase complex mutations analyzed. Five patients (with TERT mutations) had two clones expanded and one (with TERC mutation) showed three overrepresented clones. The Vβ subsets 9, 13.6, 17, and 20 were expanded in more than one patient. Oligoclonal Vβ expansion was not observed in Fanconi anemia. Telomerase mutant patients also had significantly increased interferon-γ serum levels in comparison to controls (27 pg/mL; range, 0–95 vs. 7.6, 0–16, respectively; P<0.02). These results indicate that an immune process targeting hematopoiesis may operate in patients carrying telomerase complex gene mutations. Limited responsed to immunosuppression may reflect the poor hematopoietic reserve rather than a nonimmunologic mechanism of marrow destruction.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2043-2043
Author(s):  
Neelam Giri ◽  
Christine Mueller ◽  
Sarah Weinstein ◽  
Suvimol Hill ◽  
John Butman ◽  
...  

Abstract Inherited bone marrow failure syndromes (IBMFS) comprise a group of heterogeneous genetic disorders characterized by single or multilineage cytopenias, distinctive clinical features, and an increased risk of specific malignancies, with considerable overlap in hematologic and physical manifestations. Our objective was to identify specific distinguishing features for each of the major IBMFS by identical systematic evaluations, in the first comparison of all 4 disorders in a single center. Participants were: 23 with Fanconi anemia (FA), 32 with dyskeratosis congenita (DC), 23 with Diamond-Blackfan anemia (DBA) and 7 with Shwachman-Diamond syndrome (SDS). Evaluations included physical characteristics, hematologic data, and abnormalities of the skeletal, ophthalmic, otologic, renal, cardiac, central nervous system (CNS) and endocrine systems. We found a similar frequency of cytopenias (~80%) in all disorders; predominantly multilineage in FA and DC, anemia in DBA, and neutropenia in SDS. 50% of FA patients had clonal marrow cytogenetic abnormalities, of whom 24% had morphologic myelodysplastic syndrome (MDS); 25% of DC patients had clones of whom one had MDS; none with DBA had a clone or MDS; and 4/7 with SDS had clones [i(7)q in one, del(20)q in two, i(X)p in one] but no MDS. Skeletal malformations were frequent in patients with FA (68%). Anomalies unique to FA were radial ray defects (thumb or thumb and radius) in 45%, Klippel-Feil Syndrome in 45%, and fused or partial ribs in 25%. No specific defects were seen in patients with DC or DBA. 3/7 patients with SDS had metaphyseal dysplasia. 80% of FA patients had smaller than normal eye measurements, including one or more of outer canthal distance, inner canthal distance, palpebral fissure length or interpupillary distance, compared with age and sex-matched published controls, unaffected family members and patients with other IBMFS; 75% had small eyes by A-scan and 60% had microcorneas. ~15% of patients with DC, DBA and SDS had small palpebral fissure lengths but no microcorneas. Eye findings unique to DC were lacrimal duct stenosis in 27%, exudative retinopathy in one and proliferative retinopathy with retinal neovascularization in two. Hearing was decreased only in FA, in 65%, associated with abnormalities of tympanic membrane bony island and/or short malleus, with conductive hearing loss in 40%. 40% of FA patients had renal anomalies vs. 3% with DC, 8% with DBA and none with SDS. Congenital cardiac defects were more frequent in patients with DBA (40%) than in those with FA (15%), DC (3%) or SDS (none). 50% of patients with FA, 25% with DBA and 5/7 patients with SDS had short stature (height Z-score <2SD) and microcephaly, whereas in DC only 3% had short stature, and 38% had microcephaly without short stature. Only patients with FA and DC had abnormal brain MRIs: 27% of FA patients had absent corpus callosum and/or septum pellucidum, and 57% had a small pituitary; 38% of DC patients had cerebellar hypoplasia and associated microcephaly, developmental/speech delay and ataxia. 56% of DC patients had at least two features of the diagnostic triad (nail dystrophy, oral leukoplakia, and lacey skin pigmentation). Endocrine abnormalities which were common in FA [hypothyroidism (35%), growth hormone deficiency (25%) and hypogonadism (>90% adults)] were rare in the other IBMFS. However, 90% of the patients with FA, 27% with DC, and 60% with DBA and SDS had reduced bone mineral density on Dexa scan. In this first direct, single center comparison of the 4 major IBMFS, we identified: skeletal anomalies, small eyes, abnormal hearing and endocrine deficiencies in FA; high rates of cardiac defects in DBA; CNS anomalies in FA and DC; microcephaly in all disorders; and reduced bone mineral density in all 4 disorders but highest in FA. Thus, comprehensive systematic investigations detected unique syndrome-specific abnormalities in much higher frequencies than expected based on literature reports. These findings have important clinical consequences and warrant early intervention.


2013 ◽  
Vol 133 (6) ◽  
pp. 1513-1515 ◽  
Author(s):  
Blanche P. Alter ◽  
Neelam Giri ◽  
Sharon A. Savage ◽  
Wim G.V. Quint ◽  
Maurits N.C. de Koning ◽  
...  

Blood ◽  
2012 ◽  
Vol 119 (16) ◽  
pp. 3815-3819 ◽  
Author(s):  
Adrianna Vlachos ◽  
Philip S. Rosenberg ◽  
Eva Atsidaftos ◽  
Blanche P. Alter ◽  
Jeffrey M. Lipton

Abstract Diamond Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by red cell aplasia and congenital anomalies. A predisposition to cancer has been suggested but not quantified by case reports. The DBA Registry of North America (DBAR) is the largest established DBA patient cohort, with prospective follow-up since 1991. This report presents the first quantitative assessment of cancer incidence in DBA. Among 608 patients with 9458 person-years of follow-up, 15 solid tumors, 2 acute myeloid leukemias, and 2 cases of myelodysplastic syndrome were diagnosed at a median age of 41 years in patients who had not received a bone marrow transplant. Cancer incidence in DBA was significantly elevated. The observed-to- expected ratio for all cancers combined was 5.4 (P < .05); significant observed-to-expected ratios were 287 for myelodysplastic syndrome, 28 for acute myeloid leukemia, 36 for colon carcinoma, 33 for osteogenic sarcoma, and 12 for female genital cancers. The median survival was 56 years, and the cumulative incidence of solid tumor/leukemia was approximately 20% by age 46 years. As in Fanconi anemia and dyskeratosis congenita, DBA is both an inherited bone marrow failure syndrome and a cancer predisposition syndrome; cancer risks appear lower in DBA than in Fanconi anemia or dyskeratosis congenita. This trial was registered at www.clinicaltrials.gov as #NCT00106015.


Hematology ◽  
2005 ◽  
Vol 2005 (1) ◽  
pp. 96-103 ◽  
Author(s):  
Blanche P. Alter

Abstract Aplastic anemia may be inherited or acquired. The distinction between these lies not in the age of the patient, but in the clinical and laboratory diagnoses. Adult hematologists must consider adult presentations of the inherited disorders, in order to avoid incorrect management of their patients. Physicians for adult patients must also realize that children with inherited disorders now survive to transition into their care. The major inherited bone marrow failure syndromes associated with development of pancytopenia include Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and amegakaryocytic thrombocytopenia. The ages at presentation are highly variable, but often include individuals of adult age who have previously undiagnosed Fanconi anemia or dyskeratosis congenita. Many of the genes responsible for these disorders have been identified (12 Fanconi anemia genes, 3 dyskeratosis congenita genes, and 1 each for Shwachman-Diamond syndrome and amegakaryocytic thrombocytopenia). A high index of suspicion and specific testing of children or adults with what appears to be acquired aplastic anemia may identify inherited disorders. Correct classification of patients with aplastic anemia of any age is mandatory for their appropriate management.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 996-996
Author(s):  
Neelam Giri ◽  
Sara Khaghani ◽  
Blanche P. Alter

Abstract Fanconi anemia (FA) and dyskeratosis congenita (DC) are genetic disorders characterized by bone marrow failure and an increased risk of acute myeloid leukemia, myelodysplastic syndrome (MDS) and epithelial cancers. While immunological abnormalities have been reported in small numbers of FA and DC patients, their correlation with the evolution of hematologic and neoplastic complications is unclear. To investigate these associations in a prospective cohort we evaluated serum immunoglobulins (IgG, IgA, IgM) and lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+ ratio, B, and NK cells) in 17 FA and 18 DC patients enrolled in the National Cancer Institute’s Inherited Bone Marrow Failure Syndrome (IBMFS) study. All patients were seen at the NIH Clinical Center and had not undergone bone marrow transplantation or received immunosuppressive treatment including corticosteroids in the past 2 years. Their clinical, hematological, immunological and neoplastic features at study entry are summarized in the table. Abnormal values were defined as below the normal range (95% CI). Parameter FA (n=17) DC (n=18) Median age in years (range) 18 (5–42) 17 (3–47) Any hematological abnormality 12 (71%) 16 (89%) Any cytopenia 9 (53%) 16 (89%) MDS 3 (18%) 0 Low absolute lymphocyte count 1 (16%) 0 Low IgG, IgA, or IgM 6 (35%) 5 (28%) High IgG, IgA, or IgM 0 7 (38%) Low lymphocyte subset 4/6 (67%) 4/10 (40%) Low immunoglobulins and/or lymphocytes 8 (47%) 9 (50%) Neoplasm 5 2 Fanconi Anemia: 6/17 patients had low immunoglobulin levels. All 5 with normal complete blood counts (CBC) had normal immunoglobulin levels. Among 3 with MDS, 1 had low IgG, IgA and IgM. Among 9 with cytopenias 1 had low IgG, IgA and IgM and 4 had low IgM. Thus 0/5 with normal CBC versus 6/12 with abnormal CBC had at least one low immunoglobulin level (p=0.1). 4/6 patients had abnormal lymphocyte subset numbers; all 4 had decreased CD4+, CD19+ cells and an abnormal CD4+/CD8+ ratio (&lt;1) and 2 had low NK cells. 2/4 with abnormal lymphocyte subset numbers had neoplasms (1 head and neck squamous cell carcinoma [HNSCC], 1 liver adenoma). Taken together, 1/5 with normal CBC (this patient had HNSCC) had abnormal immune parameters (decreased CD4+, CD19+ cells and an abnormal CD4+/CD8+ ratio), compared with 7/12 with abnormal CBC (p=0.15). 2/9 FA patients with normal and 3/8 with abnormal immune parameters had neoplasms (1 lymphoma and vulvar SCC in the former; 1 liver adenoma, 1 HNSCC + MDS, 1 HNSCC in the latter) (p=0.6). Dyskeratosis congenita: 5/18 patients had low immunoglobulin levels (2 IgA, 2 IgG, 1 IgM), and 7 had high levels (2 IgG and IgA, 5 IgA; 1 patient had low IgM and high IgA). 4/10 also had reduced lymphocyte subset numbers (3 low NK cells; 1 low CD19+, CD3+, CD4+ and abnormal CD4+/CD8+ ratio). 9/16 patients with abnormal CBC had abnormal immune studies versus 0/2 with normal CBC (p=1). 1/2 DC patients with SCC had low IgM. Our preliminary screening identified decreased immunoglobulins and/or lymphocytes in ~50% of the FA and DC patients. The decreases were associated with hematological and/or neoplastic complications in all cases. Since CD4+ cells participate in regulation of myeloid hematopoiesis, abnormal numbers of CD4+ cells may contribute to bone marrow failure. Defects in T-helper and NK cell differentiation may increase the risk of neoplasms. Further and larger studies are required to determine the functional importance of these preliminary observations and their correlation with bone marrow failure, MDS, leukemia, or solid tumors.


Sign in / Sign up

Export Citation Format

Share Document